[LB-01] Late Breaking Symposium

[LB-01-03] Biomarker analysis of Phase II Trial of OCH-NCNP1 for Patients with Relapsing Multiple Sclerosis

Wakiro Sato
Tomoko Okamoto
Youwei Lin
Takami Ishizuka
Harumasa Nakamura
Daiki Takewaki
Wataru Suda
Noriko Sato
Yukio Kimura
Masanori Taketsuna
Yu Okada
Takashi Yamamura

(Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan)
(Department of Neurology, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan)
(Clinical Research Support Office, Translational Medical Center, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan)
(Laboratory for Microbiome Sciences, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan)
(Department of radiology, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan)
(Translational Research Center for Medical Innovation, Foundation or Biomedical Research and Innovation, Hyogo, Japan)